Core Insights - The gut microbiome is a significant predictor of health, influencing metabolism, weight, brain health, and aging [3][4] - Dysbiosis, or an imbalance in gut microbes, is linked to various chronic diseases, including obesity, cardiovascular disease, and neurodegenerative disorders [22][30] Group 1: Microbiome and Health - The gut microbiome consists of over 30 trillion microbes, comparable in number to human cells, and plays a crucial role in digestion and nutrient absorption [5][10] - Changes in the microbiome can occur rapidly in response to diet, antibiotics, and environmental factors, affecting overall health and resilience [8][13] - Dysbiosis can lead to increased intestinal permeability, systemic inflammation, and is associated with conditions like metabolic syndrome and autoimmune diseases [22][23][24] Group 2: Chronic Diseases Linked to Dysbiosis - Cardiovascular disease is linked to dysbiosis through microbial metabolites such as trimethylamine N-oxide (TMAO), which is associated with higher risks of heart attack and stroke [25][31] - Neurodegenerative diseases like Alzheimer's and Parkinson's show microbial shifts that may precede clinical symptoms, suggesting potential for early intervention [28][51] - Mental health issues, including major depressive disorder, have been correlated with reduced levels of beneficial gut bacteria [27][32] Group 3: Dietary Influence on the Microbiome - A diverse, plant-based diet rich in fiber, resistant starches, and polyphenols is essential for maintaining a healthy microbiome [35][39][54] - Fermented foods can enhance microbial diversity and reduce inflammation, supporting overall gut health [38][54] - Long-term dietary changes are necessary to achieve lasting improvements in microbiome composition, as short-term diets often revert to baseline [42][44] Group 4: Future of Microbiome Research and Therapies - Precision probiotics and live biotherapeutic products (LBPs) are being explored as potential treatments for metabolic and neurological disorders [46][49] - Emerging diagnostics, such as stool sequencing and capsule-based sampling, may allow for personalized microbiome-targeted therapies [51][52] - The integration of diet, lifestyle, and microbial therapeutics is anticipated to be the future approach for optimizing gut health and overall well-being [52][53]

公司经营产生负现金流，绝大部分经营现金外流是研发及行政活动产生。2023年、2024年，经营活动所 用现金净额分别为1.92亿元、3.68亿元。2025年上半年，经营活动所用现金净额为0.003亿元。通过推出 及商业化产品、降本增效、发展意向合作、订立授权安排，公司预计经营活动产生的现金流会增加。 9月15日，杭州新元素药业股份有限公司向港交所递交上市申请。 2023年、2024年及2025年上半年，公司分别净亏损0.97亿元、4.34亿元及1.65亿元。公司的亏损主要来 自研发开支及行政开支。公司尚未有产品进入商业化阶段，核心产品存在研发及市场推广不确定性风 险。 尚无产品获批商业销售 招股书显示，新元素药业成立于2012年，是一家专注在代谢、炎症和心血管疾病领域开发具有全球竞争 力和商业价值疗法的生物技术公司，涵盖痛风患者的全流程护理，全方位解决高尿酸血症、慢性痛风、 急性痛风、痛风石溶解及与合并高尿酸血症慢性肾病（CKD）等问题。目前，公司建立了一条包括两 款临床阶段产品及多个临床前阶段项目。 公司计划把握以下机遇，并相应实施公司的主要战略：第一，加速核心产品ABP-671的全球商业化进 程；第二，加速 ...

9月15日，杭州新元素药业股份有限公司向港交所递交上市申请。 2023年、2024年及2025年上半年，公司分别净亏损0.97亿元、4.34亿元及1.65亿元。公司的亏损主要来 自研发开支及行政开支。公司尚未有产品进入商业化阶段，核心产品存在研发及市场推广不确定性风 险。 尚无产品获批商业销售 研发开支较大 2023年、2024年及2025年上半年，新元素药业研发开支分别约为1.77亿元、3.38亿元、0.74亿元，其中 用于核心产品研发的开支分别为1.55亿元、2.84亿元、0.63亿元，分别占相应年度/期间总研发开支的 87.9%、83.9%、85.5%。2025年上半年ABP-671研发开支同比减少，是因为临床开发取得进展。随着公 司持续推进ABP-6712b/3期临床试验，预计ABP-671继续产生重大研发开支。 招股书显示，新元素药业成立于2012年，是一家专注在代谢、炎症和心血管疾病领域开发具有全球竞争 力和商业价值疗法的生物技术公司，涵盖痛风患者的全流程护理，全方位解决高尿酸血症、慢性痛风、 急性痛风、痛风石溶解及与合并高尿酸血症慢性肾病(CKD)等问题。目前，公司建立了一条包括两款临 床阶段产 ...

Core Viewpoint - The article discusses new evidence regarding nicotine's potential anti-aging effects, suggesting that nicotine can reprogram aging-related metabolism and protect against motor decline in mice [3]. Group 1: Research Findings - A study published by researchers from the Shenzhen Institute of Advanced Technology indicates that chronic low-dose nicotine acts as an activator of NAD⁺ biosynthesis, improving glucose metabolism and cognitive function in mice [8]. - The research highlights that the beneficial effects of nicotine occur at significantly lower concentrations than those typically associated with smoking, emphasizing the need for further studies on nicotine dosage and duration [10]. - The study also found that long-term oral nicotine treatment can mitigate age-related declines in motor function in mice, with no pathological changes observed in peripheral organs related to metabolism [11][13]. Group 2: Aging and Metabolism - Aging is characterized by systemic physiological deterioration, including metabolic dysregulation and reduced physical activity, which are critical factors for healthy aging [5]. - Recent advancements in aging research utilize multi-dimensional omics and machine learning to depict biological aging trajectories, revealing the interconnectedness of energy metabolism, mitochondrial efficiency, and nutrient signaling networks [6]. - The decline in NAD⁺ levels during aging negatively impacts cellular energy homeostasis and genomic integrity, while restoring NAD⁺ can alleviate age-related decline [6]. Group 3: Nicotine's Biological Activity - Epidemiological data show a paradoxical relationship between smoking and certain diseases, where nicotine may have protective associations against conditions like ulcerative colitis and Parkinson's disease [7]. - The study indicates that nicotine influences the gut microbiome, which plays a crucial role in overall physiology, and its effects vary depending on conditions, necessitating context-specific analyses [10]. - Nicotine's impact on sphingolipid metabolism is linked to improved energy metabolism and reduced accumulation of neurotoxic ceramides, which are associated with age-related muscle dysfunction [13][15].